VRTX — Vertex Pharmaceuticals Incorporated

Ownership history in Bellevue Group AG  ·  40 quarters on record

This page tracks every 13F SEC filing in which Bellevue Group AG reported a position in Vertex Pharmaceuticals Incorporated (VRTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
5.87% (2020 Q1)
Avg. % of fund
3.34%
First filed
2016 Q1
Last filed
2025 Q4
Quarters held
40
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 681,120 +175,315 +34.7% 5.85% $308.8M $453.36
2025 Q3 ADDED 505,805 +64,195 +14.5% 4.12% $198.1M $391.64
2025 Q2 ADDED 441,610 +28,539 +6.9% 4.33% $196.6M $445.20
2025 Q1 REDUCED 413,071 -74,363 -15.3% 4.49% $200.3M $484.82
36 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    VRTX price (monthly, adj. close)

Other funds also holding VRTX

As of 2025 Q4 — sorted by position size

Provident Investment Management, Inc. 3Y 7Y 6.16% Andrew Hill Investment Advisors, Inc. 3Y 4.28% Iron Triangle Partners LP 3Y 3.99% Atle Fund Management AB 3Y 7Y 3.32% MCRAE CAPITAL MANAGEMENT INC 3Y 7Y 3.29% Sofinnova Investments, Inc. 3Y 7Y 3.22% SECTORAL ASSET MANAGEMENT INC 3Y 7Y 2.91% Birch Hill Investment Advisors LLC 3Y 7Y 2.89% NIA IMPACT ADVISORS, LLC 3Y 2.68% AIMZ Investment Advisors, LLC 3Y 7Y 2.63%
← Back to Bellevue Group AG Holdings